Clinical Trial

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-17; most recent amendment 2026-03-02.
Status change: Recruiting → Completed 2026-03-02
Status change: Not Yet Recruiting → Recruiting 2025-09-12
Trial Details
NCT Number NCT07088913
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants
Enrollment 20 participants
Start Date 2025-07-28
Primary Completion 2026-02-20 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-03